Somying Patntirapong1. 1. Thammasat University Research Unit in Dental and Bone Substitute Biomaterials, Faculty of Dentistry, Thammasat University, Pathumthani, Thailand.
Abstract
Background: Alendronate is a drug for the treatment of excessive bone resorption. Alendronate reduces osteoblast viability and mineralization in a dose-dependent manner. Other views of alendronate could affect mineralization. Therefore, the effects of timing and duration of alendronate treatment on mineralization were investigated. Materials and methods: MC3T3 cells were treated with alendronate at different time periods ranging from 1 to 3 weeks. Mineralization was quantified using image analysis. Cell viability was measured by Thiazolyl Blue Tetrazolium Bromide assay. Results: At low concentration (1 μM), 2-3 weeks of alendronate addition decreased mineralized area and staining intensity. Longer exposure to alendronate had more effect than short exposure. At moderate to high concentrations (5-10 μM), every alendronate treatment timing inhibited mineralization. Week 3 treatment of alendronate showed less reduction of mineralization than other time treatments. Furthermore, 10 μM alendronate reduced osteoblast viability at week 1, week 1-2, and week 1-3. Conclusion: Timing and duration of alendronate addition inhibited total mineralization. Longer period of treatment reduced mineralization more than short period of treatment. In addition, reduction of total mineralization depended upon both osteoblast viability and function.
Background: Alendronate is a drug for the treatment of excessive bone resorption. Alendronate reduces osteoblast viability and mineralization in a dose-dependent manner. Other views of alendronate could affect mineralization. Therefore, the effects of timing and duration of alendronate treatment on mineralization were investigated. Materials and methods: MC3T3 cells were treated with alendronate at different time periods ranging from 1 to 3 weeks. Mineralization was quantified using image analysis. Cell viability was measured by Thiazolyl Blue Tetrazolium Bromide assay. Results: At low concentration (1 μM), 2-3 weeks of alendronate addition decreased mineralized area and staining intensity. Longer exposure to alendronate had more effect than short exposure. At moderate to high concentrations (5-10 μM), every alendronate treatment timing inhibited mineralization. Week 3 treatment of alendronate showed less reduction of mineralization than other time treatments. Furthermore, 10 μM alendronate reduced osteoblast viability at week 1, week 1-2, and week 1-3. Conclusion: Timing and duration of alendronate addition inhibited total mineralization. Longer period of treatment reduced mineralization more than short period of treatment. In addition, reduction of total mineralization depended upon both osteoblast viability and function.
Authors: Sven Otto; Mario Hakim Abu-Id; Stefano Fedele; Patrick H Warnke; Stephan T Becker; Andreas Kolk; Thomas Mücke; Gerson Mast; Robert Köhnke; Elias Volkmer; Florian Haasters; Olivier Lieger; Tateyuki Iizuka; Stephen Porter; Giuseppina Campisi; Giuseppe Colella; Oliver Ploder; Andreas Neff; Jörg Wiltfang; Michael Ehrenfeld; Thomas Kreusch; Klaus-Dietrich Wolff; Stephen R Stürzenbaum; Matthias Schieker; Christoph Pautke Journal: J Craniomaxillofac Surg Date: 2010-07-02 Impact factor: 2.078
Authors: Andrej Skerjanec; James Berenson; ChyiHung Hsu; Pierre Major; Wilson H Miller; Christina Ravera; Horst Schran; John Seaman; Felix Waldmeier Journal: J Clin Pharmacol Date: 2003-02 Impact factor: 3.126
Authors: U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus Journal: N Engl J Med Date: 1995-11-30 Impact factor: 91.245
Authors: Mark A Scheper; Ashraf Badros; Andrew R Salama; Gary Warburton; Kevin J Cullen; Dianna S Weikel; Timothy F Meiller Journal: Support Care Cancer Date: 2009-08-04 Impact factor: 3.603